UA140106U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

A method of predicting the development of osteoarthritis, in which perform a clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of the gene for methylenetetrahydrofolate reductase (MTHFR C677T), the content of endothelin, folic acid, transforming growth factor beta 1 (TGF-1), homocysteine and with homozygous carrier of folate 677 / T <6 ng / ml, TGF- / 1 <14 ng / ml, homocysteine> 20 μmol / l predict the development of osteoarthritis.

Description

The proposed useful model The method of predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEV C677T), the content of endothelin, folic acid, transforming growth factor beta 1 (TGF-VDI1), homocysteine, and homozygous carriers of 677- HT, endothelin content 210 ng/ml, folic acid 6 ng/ml, TFR-B1I 14 ng/ml, homocysteine 20 μmol/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, an X-ray is taken, and the MTNEV C677T gene polymorphism is determined. The content of endothelin, folic acid, TFR-VI, and homocysteine is determined by the immunoenzymatic method. With homozygous carrier 677-177, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, TFR-DV1 "14 ng/ml, homocysteine 220 μmol/l predict the development of osteoarthritis.

A specific example of using the method

Patient D., 59 years old, was admitted to the clinic due to pain syndrome in the right knee joint. Examined, X-ray taken. No signs of osteoarthritis were found. Polymorphism of MTNEV C677T gene was determined in blood serum. The content of endothelin, folic acid, TGF-B1, and homocysteine was determined by immunoenzymatic method. Established homozygous carrier 677-

TT. Levels of endothelin - 22 ng/ml, folic acid - 3.5 ng/ml, TFR-B1 - 8.2 ng/ml, homocysteine - 39 μmol/l. The development of osteoarthritis was diagnosed. After 13 months, X-rays revealed

From the phenomenon of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, in which a clinical examination and radiography are performed, which is distinguished by the fact that the polymorphism of the methylenetetrahydrofolate reductase gene (MITNEV Сб677Т), the content of endothelin, folic acid, transforming growth factor beta 1 (TGF-DV1), and homocysteine are additionally determined in the patient's blood serum and with homozygous carrier 677-171 and levels of endothelin 210 ng/ml, folic acid "6 ng/ml, TFR-RI "14 ng/ml, homocysteine 220 μmol/l predict the development of osteoarthritis.